RAAS
RAAS
RAAS the company has been adhering to the quality policy
RAAS was founded in 1988 and listed on the Shenzhen Stock Exchange in 2008 (stock code: 002252), is a leading blood products company in Asia. Since its establishment 28 years ago, the company has been adhering to the quality policy of "safety, quality and efficiency", and has developed 11 products covering three categories of blood products: human blood protein, human immunoglobulin and coagulation factors, including human albumin, human immunoglobulin, static human immunoglobulin, hepatitis B human immunoglobulin, tetanus toxoid, and human immunoglobulin. Human immunoglobulin, rabies human immunoglobulin, human prothrombin complex, human coagulation factor VIII, lyophilized human thrombin, human fibrinogen, topical lyophilized human fibrin binder. Shanghai RAAS has been registered in nearly 20 countries, and is one of the few domestic manufacturers that can export blood products. Up to now, Shanghai RAAS has 33 plasma stations in China including those under construction, with an annual production capacity of 900 tons of plasma and more than 25 million vials of blood products.
- All
- News
- Analysis
- Research
Briefing Dec 04, 2021 09:35 AM
· Healthcare
Keytruda melanoma can adapt to a wider range of patients
Briefing Dec 04, 2021 09:31 AM
· Healthcare
Fuhong Hanlin bevacizumab approved in China
In depth
Healthcare
Bid for Molecular Tech in China's Early-Stage Cancer Detection Market
China, with a population of 1.4 billion, has one of the largest gene pools in the world. How does its DNA tech-based cancer detection industry look? Listed on Nasdaq in 2020, Genetron Holdings Limited (Genetron Health) is taking a leading role.
Sep 09, 2020 03:08 PM
Briefing Dec 03, 2021 06:31 PM
· Healthcare
Beida pharmaceutical's second Hong Kong stock IPO
Briefing Dec 03, 2021 10:00 AM
· Healthcare
The world's leading intelligent hearing aid "Zhiyin" won tens of millions of yuan of pre-A investment, which was invested by Qingsong fund, Xiaomi war investment and Shunwei capital
Apr 22, 2021 03:11 PM
Research
Healthcare, Technology, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Research
Real Estate, Industrials, FinancialsTech for Global, Globalization Footprints of the Established and the New
May 29, 2020 08:30 PM
Briefing Dec 02, 2021 08:29 PM
· Financials
Shanghai Laishi: Kerui Tiancheng investment holding has passively reduced its stake of 2.09%
Briefing Dec 02, 2021 09:54 AM
· Healthcare
Pfizer vaccine R & D director will switch to GlaxoSmithKline
Briefing Dec 02, 2021 09:44 AM
· Healthcare
Sanofi plans to acquire origimm and distribute acne vaccine
Briefing Dec 02, 2021 09:42 AM
· Healthcare
Xiansheng pharmaceutical's application for listing license of traracillin, a comprehensive bone marrow protection drug, was accepted
Briefing Dec 01, 2021 05:58 PM
· Healthcare
The first phase I clinical trial of CSF-1R antibody drug in China was completed, and the first patient was administered
Briefing Nov 29, 2021 06:24 PM
· Healthcare
Aibo biology completed the round C + financing of US $300 million
Briefing Nov 29, 2021 02:14 PM
· Healthcare
Yuanyin biology completed the pre-A round of financing of more than 100 million yuan
Insight
Briefing Oct 13, 2021 06:53 PM
· Consumer Staples
Shanghai Laishi: Laishi China plans to passively reduce its holdings of no more than 10.24 million shares
Briefing Sep 08, 2021 08:43 PM
Shanghai Laishi: the controlling shareholder and actual controller are changed to none
Briefing Aug 13, 2021 08:13 PM
· Technology
Shanghai Laishi: Kerui Tiancheng and those acting in concert have passively reduced 672 million shares
See more
Related Companies
EqualOcean Analysis
- Genetron Health's Self-Developed Mutation Capsule Differentiates It from Others
- Black Swans and Breakthroughs: China's Top 50 Innovative Public Firms in 2020
- China Speed: Two COVID-19 Vaccines Recognized by WHO
- After China's BNR and GTH Hit Nasdaq, Pan-Cancer Detector GRAIL Eyes IPO
- More Room for the Medical Device Market to Grow in China
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.